Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 26 Major JPMA Member Companies Report Declines in Sales, Profits, with 8.8% Drop in Overseas Sales
November 25, 2011
- Takeda Files NDA for Fixed-Dose Combination of DPP-4 Alogliptin, Metformin with US FDA
November 25, 2011
- MTPC: Telavic Tablets 250 mg to Treat Chronic Hepatitis C
November 25, 2011
- MTPC, Novartis Pharma: Imusera 0.5 mg/Gilenya 0.5 mg for Treatment of MS
November 25, 2011
- Asahi Kasei: Teribone SC Injection 56.5 µg for Treatment of Osteoporosis
November 25, 2011
- 25 Leading Drug Makers Report Overall Decline in Sales, Profits in 1st Half
November 24, 2011
- Astellas President Hatanaka Highly Expects “Bio-Lead Project
November 22, 2011
- Sakai Chemical to Make Kaigen Wholly Owned Subsidiary
November 22, 2011
- ASKA Aims at ¥20 Billion Sales in Generics Business: President Yamaguchi
November 22, 2011
- Ajinomoto, Interprotein Sign Joint R&D Agreement for PPI Inhibitors
November 22, 2011
- Sanofi, Nichi-Iko to Copromote Latter's Generic Drugs
November 22, 2011
- US FDA Accepts NDA for Once-monthly Depot Formulation of Abilify
November 22, 2011
- US Court Issues Amended Ruling in Litigation Between Asahi Kasei Pharma, Actelion
November 22, 2011
- OncoTherapy to File for Therapeutic Pancreatic Cancer Vaccine in Sept. 2012
November 22, 2011
- Sawai, Nichi-Iko Boost Inventory Ahead of Expected PAL Amendment
November 21, 2011
- FDA Extends Action Date for Takeda’s Alogliptin for 3 Months
November 21, 2011
- Eli Lilly Japan to Provide Alimta to Research for Free
November 21, 2011
- Novartis, Eisai to Copromote Onbrez
November 21, 2011
- MTPC, JRCS to Postpone Integration of Plasma Fractionation Products Business to Oct 2012
November 21, 2011
- Daiichi Sankyo Forms Subsidiary in China to Manage Local Operations
November 21, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…